Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
Clinical trial NCT07450040 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07450040
- Sponsor
- Eye & ENT Hospital of Fudan University
- Status
- ENROLLING_BY_INVITATION
- Study type
- OBSERVATIONAL
- Start date
- 2024-09-12
- Primary completion
- 2027-07-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.